Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts within the central nervous system to alleviate depressive conditions and related symptoms. - Major depressive disorder: reduces depressive mood, improves sleep and appetite. - Depression with prominent anxiety: alleviates anxiety symptoms alongside mood improvement. - Depression with insomnia: promotes sleep while treating core depressive features.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Blurred vision

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic dysfunction - Suicidal thoughts or behavior - Seizures - Severe allergic reactions (anaphylaxis)

Before initiating therapy, clinicians should consider several safety aspects. - Assess hepatic function: adjust use in patients with liver impairment. - Monitor weight: anticipate possible weight gain and counsel on nutrition. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Caution in elderly: increased sensitivity to sedation and orthostatic hypotension. - Review concomitant CNS depressants: risk of additive sedation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (alcohol, benzodiazepines): additive sedation. - CYP2D6 inhibitors (e.g., paroxetine): increased mirtazapine plasma levels. - Other serotonergic agents (SSRIs, SNRIs, tramadol): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihistamines: enhanced sedative effect. - Warfarin: possible increase in INR, monitor coagulation. - Lithium: monitor serum lithium levels for potential toxicity.